Literature DB >> 2430072

Treatment of non-small-cell lung cancer.

J L Mulshine, E Glatstein, J C Ruckdeschel.   

Abstract

The treatment of non-small-cell lung cancer (NSCLC; including squamous, large-cell anaplastic, and adenocarcinoma) is one of the most frustrating areas in oncology. With the exception of the high cure rates for surgical treatment of truly localized disease, the prognosis for patients with NSCLC is grim. Often rancorous debate has ensued about the best means of exploiting the currently available modalities of radiation therapy and chemotherapy. Recognizing that the effectiveness of the current therapeutic modalities is limited, we will review the treatment results from the past few years that help define where specific treatment options should be used or suggest areas in which to focus future trials. We will also review the implications of current findings in the cell biology of lung cancer as they pertain to the therapy of NSCLC.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2430072     DOI: 10.1200/JCO.1986.4.11.1704

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

1.  Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan).

Authors:  M Sakurai; T Shinkai; K Eguchi; Y Sasaki; T Tamura; K Miura; Y Fujiwara; A Otsu; N Horiuchi; H Nakano
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

Review 2.  Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy.

Authors:  Jason H Tang; David Chia
Journal:  Crit Rev Oncog       Date:  2015

3.  Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patients.

Authors:  J L Pujol; D Cupissol; C Gestin-Boyer; J Bres; B Serrou; F B Michel
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC).

Authors:  P Weynants; Y Humblet; A Bosly; D Schallier; P Duprez; F Majois; M Beauduin; J Prignot; M Symann
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

5.  A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.

Authors:  L Crino; M Tonato; S Darwish; M L Meacci; E Corgna; F Di Costanzo; F Buzzi; G Fornari; E Santi; E Ballatori
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party.

Authors: 
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

7.  Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.

Authors:  J L Pujol; E H Cooper; M Lehmann; D A Purves; M Dan-Aouta; J Midander; P Godard; F B Michel
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

8.  A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party.

Authors: 
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

9.  Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill.

Authors:  D W Wilbur; E S Camacho; D A Hilliard; P L Dill; L M Weisenthal
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

10.  Correlation of neuroendocrine features with prognosis of non-small cell lung cancer.

Authors:  Jianguo Feng; Huaying Sheng; Chihong Zhu; Xiaoqian Qian; Danying Wan; Dan Su; Xufeng Chen; Liming Zhu
Journal:  Oncotarget       Date:  2016-11-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.